Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KNS366 is a first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitor which is being investigated for the treatment of acute and chronic inflammatory disorders like acute pancreatitis and acute kidney injury.
Lead Product(s): KNS366
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: KNS366
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
KNS366 is a first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitor, which is being evaluated for the treatment of acute and chronic inflammation.
Lead Product(s): KNS366
Therapeutic Area: Immunology Product Name: KNS366
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
This financing will be used to build out its core team and to fund preclinical indication expansion studies as well as to initiate development of oral formulations of KMO inhibitors.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Epidarex Capital
Deal Size: $11.8 million Upfront Cash: Undisclosed
Deal Type: Financing April 07, 2022